山东大学齐鲁医院
Jinan, Shandong, 250012, China
NCT Number: NCT07757906
In this prospective paired diagnostic study and single-center, randomized controlled trial, patients with early esophageal squamous neoplasia or high-grade intraepithelial neoplasia meeting the inclusion and exclusion criteria will be enrolled in a paired diagnostic cohort (60 patients) and subsequently randomly assigned (1:1) to receive endoscopic submucosal dissection (ESD) with AI-based Dissection Trajectory Prediction System (ADTPS) guidance or conventional ESD (without AI). Clinical data and operator workload scores (NASA-TLX) are collected during the procedure, and postoperative follow-up assessments are performed at days 1, 3, 7, and 14. The study aims to analyze the impact of ADTPS on the mean single-dissection time and operator workload in patients undergoing ESD by comparing the efficacy differences between the experimental and control groups. Additionally, the study investigates the effects of ADTPS on other postoperative complications including R0 resection rate, muscularis propria injury, intraoperative bleeding, perforation (acute and delayed), and total procedure time; conducts a comparative analysis of the safety and efficiency of AI-assisted versus conventional ESD; and develops effective clinical strategies for optimizing dissection trajectory and reducing complications in endoscopic submucosal dissection.
This study is active but is not currently recruiting participants.
Notify Me18 year–80 year
All sexes
Interventional
Not applicable
Jinan, Shandong, 250012, China
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Lesions meeting ESD indications for esophageal, gastric, or colorectal early cancer or high-grade intraepithelial neoplasia, as defined by:
Non-invasive tumors regardless of size; or
Differentiated-type intramucosal carcinoma without ulceration, regardless of size; or
Differentiated-type intramucosal carcinoma with ulceration and a diameter ≤3 cm; or
Undifferentiated-type intramucosal carcinoma without ulceration and a diameter ≤2 cm.
Planned to undergo ESD treatment.
No prior treatment for the lesion (including ESD, surgery, radiotherapy, chemotherapy, etc.).
Platelet count >100 × 10⁹/L and PT-INR <1.5, with antiplatelet agents (aspirin, clopidogrel, etc.) discontinued for at least 5 days.
American Society of Anesthesiologists (ASA) physical status grade I or II.
Voluntarily signed informed consent.
Exclusion criteria
Patients with severe cardiopulmonary disease or other severe comorbidities that may increase the risk of the ESD procedure.
Pregnant or breastfeeding women.
The ADTPS is an artificial intelligence software system that analyzes endoscopic images in real time during ESD. It automatically identifies lesion boundaries and generates a recommended dissection trajectory overlaid on the endoscopic view. The endoscopist follows the AI-generated trajectory to perform submucosal dissection. The system provides visual guidance only and does not alter the standard surgical workflow.
The same endoscopic hardware platform is used, but the AI-based Dissection Trajectory Prediction System (ADTPS) is turned off. The endoscopist performs the ESD procedure based solely on clinical judgment and personal experience, following standard conventional ESD steps including marking, injection, circumferential incision, and submucosal dissection.
Time frame: Immediately after the ESD procedure
Time frame: During the ESD procedure
Time frame: At the time of pathological examination
Time frame: During the ESD procedure
Time frame: During the ESD procedure
Time frame: During the ESD procedure
Time frame: Within 14 days after procedure
Time frame: Within 14 days after procedure
Time frame: During the ESD procedure
Qilu Hospital of Shandong University
Other
Clinical Application of an AI-based Dissection Trajectory Prediction System (ADTPS) in Endoscopic Submucosal Dissection: A Prospective Paired Diagnostic Study and a Randomized Controlled Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07147361
Carcinoma, Carcinoma, Squamous Cell
Beijing, Beijing Municipality, China
View Trial DetailsNCT07711470
Carcinoma, Carcinoma, Squamous Cell
Beijing, China
View Trial DetailsNCT07702253
Carcinoma, Carcinoma, Squamous Cell
Hong Kong
View Trial DetailsNCT07682376
Carcinoma, Carcinoma, Squamous Cell
Harbin, Heilongjiang, China
View Trial Details